Authorized Generic "Interim" Report From FTC Offers Little Legislative Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC commissioners issue separate statements on a report that does not address the long-term effects of authorized generics.
You may also be interested in...
Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition
Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.
Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition
Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.
FTC’s Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban
Legislative effort on settlements kicks into high gear with Senate markup and a new bill that would rescind generic exclusivity in some cases.